PolyMedix, Inc. (PYMX.OB) Awarded National Science Foundation Grant for Development of Biomimetic Antimicrobial Sutures
PolyMedix, Inc., www.polymedix.com - developer of biomimetics (protein-mimicking polymers and compounds comprised of small molecules), as well as other first-in-class therapies for lethal, acute disorders via a proprietary computational drug design technology – announced today reception of a $150k National Science Foundation (NSF) grant for antimicrobial suture R&D. The Company’s two leading defensin-mimetic candidates have both completed Phase 1B clinical trials and Phase 2 is slated for this year: • PMX-60056 anticoagulant reversing agent • PMX-30063 antibiotic that mimics a defense protein from the host immune system PolyCides™ are a family of antimicrobial polymers developed by PYMX. The grant (commencing…